Stem Cells in Chronic Myeloid Leukaemia
, whereas Wnts, Notch, and Sonic hedgehog (Shh) promote HSC proliferation [2, 7, 53, 93] .
Cancer stem cells, which have been identified in many forms of leukaemia, are thought to be generated, either by mutation in a normal stem cell which already has the capacity for self-renewal, or in a progenitor cell [23, 44, 55] which then acquires self-renewal potential -thus abnormal self-renewal is considered one of the most distinguishing hallmarks of cancer cells. Selfrenewing cancer stem cells give rise to all the malignant progeny in a tumour, and if not completely eradicated by chemotherapy, they establish a reservoir of drug-resistant cells responsible for relapse after a chemotherapy-induced remission.
Biomarkers in CML
CML is an excellent example of a leukaemia in which the initiating event for early chronic phase (CP) occurs within the normal HSC compartment, yet for progression to blast crisis (BC) further mutation within the progenitor compartment with acquisition of self-renewal potential has been proposed (16, 19 Conventionally treatment response in the clinic is determined using standard laboratory techniques including full blood count, cytogenetics for Ph in BM and fluorescence in situ hybridisation and Q-RT-PCR for Bcr-Abl levels in PB.
In the setting of clinical trials this has been greatly extended to assess the ability of new drugs to block proliferation or induce cell death and to inhibit (table 1) .
Targeting Bcr-Abl Activity Using TKIs
The current first line therapy for patients with CP CML is IM (Gleevec or As a consequence of disease persistence and resistance, TKIs cannot be considered a cure for the majority of patients with CML. If used in combination these drugs may be more effective against resistance mutations, however there is no evidence that this will increase their efficacy against the stem cell population.
In the laboratory setting, mutation screens are commonly used to predict the profile of the mutations that confer TKI resistance in order to design a rational approach for combination strategies [3, 11, 19, 94, 95] . More than twenty-five amino acid substitutions at 21 positions have been identified so far to confer IM resistance in CML patients undergoing treatment [71] . Many of these mutations sterically preclude the TKI from binding to Bcr-Abl or cause a conformational change in the conserved phosphate binding (P) loop, diminishing drug binding [5, 12, 34, 37, 38] .
Recently, mathematical models capable of describing the development and 
Conclusions
CML is the first malignancy recognised to originate from a single clonal mutation. This abnormality leads to the formation of a population of CML stem cells known to be primitive, quiescent and cytokine independent. Allogeneic bone marrow transplantation is considered to be the only curative treatment for patients with CML. However, the restricted number of donors, advanced age of patients and toxicity of this approach limits its application. 
